Cinclus Pharma develops small molecules for the treatment of gastric acid related diseases. GERD is a digestive disorder causing retrograde flow of gastric juice into the esophagus. This leads to erosions, acid regurgitations and heartburn.
Cinclus Pharma was founded by pioneers in GERD treatment, both with extensive experience from Astra and AstraZeneca, where clinical phase I and phase II studies were performed on the product candidate linaprazan. Together with the team at Cinclus Pharma the founders are now taking the development of linaprazan glurate to the next level.
Cinclus Pharma’s lead drug candidate, linaprazan glurate, represents a novel class of drugs; Potassium Competitive Acid Blocker (P-CAB). A P-CAB is a fast-acting regulator of intragastric pH by a different mechanism of action than PPIs. Linaprazan glurate is firstly being developed for treatment of Gastroesophageal reflux disease (GERD), clinical studies are ongoing. Linaprazan glurate has the potential to alleviate GERD symptoms and heal esophageal injuries more effectively than current pharmaceutical therapies.
Cinclus Pharma is preparing for a growth journey, gathering a motivated and competent team, working closely together in realizing our strategy.
Sweden is the origin of many famous global biotech innovations and successful companies. Based in Stockholm, Cinclus Pharma has a unique opportunity to level up this heritage by combining experience and contemporary science with a competent and decisive board and management.
Being a clinical stage pharma company, the clinical development of linaprazan glurate is at the core of the company’s growth. Read more about the scientific progress and product development strategy at our website.
